Hims & Hers Health (HIMS) News Today

Hims & Hers Health, Inc. (NYSE: HIMS) shares have been under pressure amid reduced GLP-1 revenue guidance, multiple securities-class-action alerts and significant insider selling.

• Positive Sentiment: Zacks highlights HIMS’s strong consumer-centric telehealth model, AI-driven personalization and global expansion plans as key drivers for future growth. Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
• Neutral Sentiment: MSN reports shares are trading lower today largely due to lowered revenue guidance and looming legal headwinds. Why Hims & Hers Health Shares Are Trading Lower Today
• Negative Sentiment: Hagens Berman warns HIMS will lower revenue recognized per GLP-1 order after terminating its Novo Nordisk collaboration, triggering an ~11% sell-off and a pending securities class action. HIMS 2-WEEK DEADLINE ALERT
• Negative Sentiment: Pomerantz LLP reminds investors of a class action lawsuit against HIMS over alleged misstatements tied to its GLP-1 offering. INVESTOR ALERT: Pomerantz Law Firm
• Negative Sentiment: Kahn Swick & Foti and former Louisiana AG Charles Foti Jr. remind investors of the August 25 deadline to file lead-plaintiff applications in securities suits against HIMS. HIMS & HERS HEALTH SHAREHOLDER ALERT
• Negative Sentiment: Glancy Prongay & Murray urges investors to file lead-plaintiff motions by August 25 in the pending HIMS securities-fraud lawsuit. Deadline Alert: Hims & Hers Health Investors Urged To Contact Glancy Prongay & Murray LLP
• Negative Sentiment: HIMS shares fell over 2% after SVP Soleil Boughton sold 2,572 shares for $132,818.08. Stock Price Down 2.2% on Insider Selling
• Negative Sentiment: MarketBeat reports HIMS shares tumbled ~4.1% after renewed insider-selling pressure. Stock Price Down 4.1% Following Insider Selling
• Negative Sentiment: Finbold flags CEO Andrew Dudum’s $33.38 million share sale—the largest insider transaction since HIMS’s IPO. HIMS stock monster insider trading alert